TCTR20160125002进行中（未招募）3 期
An Efficacy of Continuing Tenofovir Versus Switching Entecavir to Tenofovir in Treatment of Chronic Hepatitis B Patients : A Comparative Study
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 0 Years（—）
- 性别
- All
入选标准
- •1. Chronic hepatitis B patient
- •2. serum HBsAg positive after received Entecavir or Tenofovir for more than 5 year
排除标准
- •1. History of malignancy, except early stage skin cancer
- •2. Decompensated cirrhosis
- •3. Creatinine clearance < 50 ml/min
- •4. Kanofsky performance status < 60
- •5. Pregnancy or lactation
研究者
相似试验
已完成
不适用
Efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide containing antiretroviral therapy in virologically suppressed HIV-infected patientsHIV infectionJPRN-UMIN000038177Kyushu University Hospital Department of General internal medicine120
已完成
2 期
Clinical trial study on the therapeutic effect of Tenofovir besides routine drug regime (standard of care) in patients with Coronavirus disease 2019 (COVID-19)covid-19.Covid-19, confirmed cases, positive test resultU07.1IRCT20200422047168N1Ahvaz University of Medical Sciences60
招募中
不适用
Efficacy of entecavir-to-tenofovir switching treatment to attain a drug-free state in chronic hepatitis B: a randomized controlled trialchronic hepatitis BJPRN-UMIN000021793Department of Hepatology, Osaka Metropolitan University90
Unknown
4 期
Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B PatientsChronic Hepatitis BNCT01491295Taipei Veterans General Hospital, Taiwan160
已完成
3 期
Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trialTenofovir disoproxil fumarate (TDF)-induced nephrotoxicity in HIV infected patientsTDF induced nephrotoxicity,switching,virological response,abacavir,lopinavir/ritonavirTCTR20190708002none84